

Freedom of Information Act 2000 – Request Reference FoI/24/451
Asthma Treatment

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of April 2024 to the end of June 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Health Board.

The below figures represent data covering the period 1 April 2024 to 30 June 2024.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	61
1.2 Dupilumab (Dupixent)	121
1.3 Mepolizumab (Nucala)	39
1.4 Omalizumab (Xolair)	43
1.5 Reslizumab (Cinqaero)	0
1.6 Tezepelumab (Tezspire)	78

Q2. How many patients were treated for severe asthma, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other
2.1 Benralizumab (Fasenra)		N/A	N/A	N/A
2.2 Dupilumab (Dupixent)				
2.3 Mepolizumab (Nucala)			N/A	
2.4 Omalizumab (Xolair)			N/A	
2.5 Reslizumab (Cinqaero)		N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)		N/A	N/A	N/A

Cardiff and Vale University Health Board (the UHB) has estimated that to complete the work needed to respond to this request would exceed the time limit as outlined in the Appropriate Limit and Fees Regulations 2004. When estimating the cost of complying with a request for information under the

applicable legislation, the UHB must calculate this cost at a rate of £25 per person per hour to a maximum of £450, with the appropriate time limit for complying therefore being 18 hours.

In completing a search for the information requested, the UHB has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records which the UHB considers would exceed the appropriate limit for the purposes of the 2004 Regulations. The UHB has therefore relied upon the exemption set out in section 12 of the Freedom of Information Act 2000 ('Exemption where cost of compliance exceeds appropriate limit') and is refusing your request.

Q3. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Please note that the figures in Q3 appear higher than in Q1 as there were issues made to more than one cost centre.

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)	60	0	5
3.2 Dupilumab (Dupixent)	27	91	5
3.3 Mepolizumab (Nucala)	33	0	8
3.4 Omalizumab (Xolair)	15	9	25
3.5 Reslizumab (Cinqaero)	0	0	0
3.6 Tezepelumab (Tezspire)	78	0	8

Q4. How many patients were treated for Asthma the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Please answer this question for ICS-LABA combination medicines e.g. Symbicort, Seretide and other branded or generic versions of the combination.

Please note that the below answers to Q4 cover *all* indications, as the UHB cannot provide disease-specific data.

Name of medicine	Pack strength	Number of patients
4.1 Fluticasone with salmeterol	All strengths	36
4.2 Fluticasone with salmeterol	500mcg fluticasone / 50mcg salmeterol	6
4.3 Budesonide with formoterol	All strengths	123
4.4 Budesonide with formoterol	400mcg budesonide / 12mcg formoterol	16

4.5 Fluticasone with vilanterol	All strengths	81
4.6 Fluticasone with vilanterol	184mcg fluticasone / 22mcg vilanterol	38
4.7 Beclometasone with formoterol	All strengths	228
4.8 Beclometasone with formoterol	200mcg beclomethasone / 6mcg formoterol	52
4.9 Fluticasone with formoterol	All strengths	8
4.10 Fluticasone with formoterol	250mcg fluticasone / 10mcg formoterol	3